Funder
National Natural Science Foundation of China
National Key Research and Development Program for Precision Medicine
Foundation for Innovative Research Groups of the National Natural Science Foundation of China
CAMS Initiative Fund for Medical Sciences
PUMC Youth Fund and the Fundamental Research Funds for the Central Universities
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Biology,Hematology
Reference68 articles.
1. Hof J, Krentz S, van Schewick C, Korner G, Shalapour S, Rhein P, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29(23):3185–93.
2. Abel GA, Bertrand KA, Earle CC, Laden F. Outcomes for lymphoid malignancies in the Nurses’ Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program. Hematol Oncol. 2010;28(3):133–6.
3. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176(5):750–8.
4. Kota VK, Hathaway AR, Shah BD, Peker D, Zhang L, Jaye DL, et al. Poor outcomes with hyper CVAD induction for T-cell lymphoblastic leukemia/lymphoma. Blood. 2015;126(23):3762.
5. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.
Cited by
117 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献